Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3643307 | 1.00 | CYP4F2 (0.31) | CYP4F2CYP4A11 | |
| SCHEMBL1635539 | 1.00 | CYP4F2 (0.31) | CYP4F2CYP4A11 | |
| SCHEMBL375254 | 0.91 | CYP4F2 (0.33) | CYP4F2CYP4A11 | |
| SCHEMBL20348813 | 0.86 | CYP4F2 (0.33) | CYP4F2CYP4A11 | |
| SCHEMBL3292857 | 0.83 | — | — | |
| SCHEMBL15928651 | 0.79 | SMN1; SMN2 (0.34) | — | |
| SCHEMBL1536298 | 0.79 | GRM2 (0.35) | — | |
| SCHEMBL7392445 | 0.79 | MAPK1 (0.36) | — | |
| SCHEMBL7392443 | 0.79 | MAPK1 (0.36) | — | |
| SCHEMBL7392441 | 0.79 | MAPK1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9636375-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-02 | — | — | US | disclosed |
| US-20160067302-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-03-10 | — | — | US | disclosed |
| US-9227940-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-05 | — | — | US | disclosed |
| EP-2049474-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-2086963-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-2300490-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-03-04 | — | — | EP | disclosed |
| US-20150005342-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-01-01 | — | — | US | disclosed |
| EP-1684745-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-12-17 | — | — | EP | disclosed |
| US-8889871-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140163231-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-06-12 | — | — | US | disclosed |
| WO-2004043339-A2 | SUBSTITUTED CYCLOALKYL P1' HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040077551-A1 | Substituted cycloalkyl P1' hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | disclosed |
| WO-2004032827-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-22 | — | — | WO | disclosed |
| US-20040072761-A1 | Heterocyclicsulfonamide hepatitis C virus inhibitors | CAMPBELL JEFFREY ALLEN (US) | 2004-04-15 | — | — | US | disclosed |
| US-20040048802-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-11 | — | — | US | disclosed |
| WO-2003099316-A1 | HETEROCYCLICSULFONAMIDE HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003099274-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| EP-1337550-A2 | HEPATITIS C TRIPEPTIDE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-08-27 | — | — | EP | disclosed |
| US-20020111313-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-08-15 | — | — | US | disclosed |
| WO-2002060926-A2 | HEPATITIS C TRIPEPTIDE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072761-A1 | Heterocyclicsulfonamide hepatitis C virus inhibitors | HCCS, ANPEP, DNPEP | CYP4F2 2912/4885CYP4A11 1549/4885 |
| US-20160067302-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, CTRB1 | CYP4F2 290/4885CYP4A11 324/4885 |
| US-20150005342-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, CTRB1 | CYP4F2 290/4885CYP4A11 324/4885 |
| US-20020111313-A1 | Hepatitis C virus inhibitors | HAVCR2, ZC3HAV1, VIP | CYP4F2 2888/4885CYP4A11 1453/4885 |
| US-20140163231-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, CTRB1 | CYP4F2 290/4885CYP4A11 324/4885 |
| US-20040048802-A1 | Hepatitis C virus inhibitors | HAVCR2, ZC3HAV1, VIP | CYP4F2 2888/4885CYP4A11 1453/4885 |
| US-20040077551-A1 | Substituted cycloalkyl P1' hepatitis C virus inhibitors | HAVCR2, ANPEP, ENPEP | CYP4F2 3199/4885CYP4A11 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.